Berman Center for Outcomes & Clinical Research
Better Care through Better Research
Since its inception in 1965, the Berman Center for Outcomes & Clinical Research has been a leader in cardiovascular research and a clinical site for over 100 trials areas such as
- heart and kidney disease
- women’s health
- neurological disorders
For several of these trials, the Berman Center initiated the investigation and was responsible for study design, implementation, and analysis. The Berman Center for Outcomes & Clinical Research is a division of Hennepin Healthcare Research Institute (HHRI), formerly known as Minneapolis Medical Research Foundation (MMRF), which is a subsidiary of Hennepin Healthcare System, Inc.
Hennepin Healthcare is an integrated system of care that includes HCMC, a nationally recognized Level 1 Trauma Center, medical research and teaching hospital located in downtown Minneapolis.
The Berman Center is compliant with Good Clinical Practice (GCP) and/or regulatory requirements consistent with “best practices” guidelines and focuses on outcomes to impact health policy and practice.
As was the intent of founder Dr. Reuben Berman, a pioneer in the field of cardiovascular clinical research, our primary mission is to empower the medical community to offer better patient care through better research.
Principal Investigators for multi-site trials for which the Berman Center has served either as a regional coordinator or as a clinical site:
Colin B, Baignet, BM * University of Oxford, Oxford, United Kingdom * SHARP, Study of Heart and Renal Protection
Merit Cudkowicz, MD * Massachusetts General Hospital/Harvard Medical School, Boston, MA * Celebrex in ALS
Robert Byington, PhD * Wake Forest School of Medicine, Winston-Salem, NC * ACCORD, Action to Control Cardiovascular Risks in Diabetes
John McNeil, PhD, MSc * Monash University, Melbourne, Australia * ASPREE, ASPirin in Reducing Events in the Elderly
Charles H. Hennekens, MD, DrPh * Mount Sinai Medical Center * TACT, Trial to Assess Chelation Therapy (Co-principal Investigator)
Gervasio A. Lamas, MD * Mount Sinai Medical Center * TACT, Trial to Assess Chelation Therapy (Co-principal Investigator)
Oscar Benavente, MD * University of Texas Health Science Center, San Antonio, TX *
SPS3, Secondary Prevention of Small Subcortical Strokes
Martin Landray, BM * University of Oxford, Oxford, United Kingdom * SHARP, Study of Heart and Renal Protection
Jeffery Probstfield, MD * University of Washington School of Medicine * ORIGIN, Outcome Reduction with Initial Glargine Intervention (Principal Investigator for U.S. Regional Coordinating Center)
Eric Sorenson, MD * Mayo Clinic, Rochester, MN * IGF-I (Myotrophin) in ALS
Hertzel Gerstein, MD * Professor of Medicine and Chief of Division of Endocrinology
McMaster University Faculty of Health Sciences
Hamilton, Ontario, Canada * ORIGIN, Outcome Reduction with Initial Glargine Intervention (Co-principal Investigator) * DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (Co-principal Investigator)
Salim Yusuf, MD * Professor of Medicine and Chief of Division of Cardiology
McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
ORIGIN, Outcome Reduction with Initial Glargine Intervention (Co-principal Investigator)
DREAM, Diabetes Reduction Assessment with Ramipril and Rosiglitazone
Medication (Co-principal Investigator) * ONTARGET/TRANSCEND
OnTarget: Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial: A large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events Transcend: Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease